Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) in Participants With Treatment-naïve, Metastatic Non-small Cell Lung Cancer (NSCLC) Whose Tumors Have a Tumor Proportion Score (TPS) Greater Than or Equal to 1%
Commercial Sponsor
Merck
Summary
Eligible participants will be randomised to receive 200mg of intravenous pembrolizumab on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS 20mg oral lenvatinib, or placebo equivalent, once daily (QD) on Days 1-21 of each 3-week cycle until progressive disease or unacceptable toxicity.